AngioDynamics pairs a bullish technical breakout and a three-quarter earnings beat streak — with another print in just 10 days — against a business quality score that sits below the engine's floor and options positioning that is unusually skewed toward puts, making this a momentum-and-catalyst trade rather than a quality-driven one.
Thesis pillars
- Quality Below Floor→Stable
- Bullish Breakout Setup→Stable
- Earnings Beat Streak→Stable
- +1 more pillar — see the Why tab for full reasoning
AngioDynamics, Inc. (ANGO) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Medical Instruments & Supplies
Sell if holding. Engine safety override at $12.79: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.75; Below-average business quality.
AngioDynamics designs, manufactures, and sells medical devices for cardiovascular disease and cancer treatment, organized into Med Tech (Auryon atherectomy, NanoKnife ablation, AlphaVac/AngioVac thrombectomy) and Med Device (vascular access, ports, drainage) segments. The... Read more
Sell if holding. Engine safety override at $12.79: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.75; Below-average business quality. Chart setup: RSI 58 mid-range, Bollinger mid-band. Score 5.9/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 6d<=7d. Suitability: aggressive.
About AngioDynamics, Inc.
About AngioDynamics, Inc.
AngioDynamics sells its cardiovascular- and cancer-focused device portfolio through two segments, Med Tech (Auryon atherectomy, NanoKnife ablation, AlphaVac and AngioVac thrombectomy) and Med Device (vascular access ports, catheters, drainage products), with international distributors accounting for approximately 74% of international revenue in fiscal 2025, a year in which international sales fell 21% following divestitures of the PICC, Midline, dialysis, and BioSentry businesses.
AngioDynamics generates revenue by selling devices directly to hospitals and physicians in the United States through its own sales force, while relying on third-party distributors outside North America in markets including China, Japan, Brazil, and the Middle East. The company manufactures many products itself at leased facilities in Queensbury and Glens Falls, New York, but is executing a restructuring plan to shift portions of manufacturing to third-party partners in Costa Rica, Latvia, Italy, Israel, and China, with completion targeted for the third quarter of fiscal 2026. The 10-K discloses that AngioDynamics is dependent on single and limited source suppliers for several key products, raw materials, and components, a risk that materialized during fiscal years 2022 and 2023 when the company experienced shortages. Sales through group purchasing organizations and integrated health delivery networks can be significant to the business, and losing those contracts could adversely affect revenue. AngioDynamics competes against larger, better-resourced rivals including Boston Scientific, Medtronic, and Becton Dickinson.
Show full overview
AngioDynamics carries litigation overhang tied to its legacy port products: numerous product liability claims previously pending in various state and federal courts have been consolidated into a single multidistrict litigation in the U.S. District Court for the Southern District of California, with the outcome still undetermined. That overhang compounds a manufacturing transition already underway — the company is moving production out of Queensbury, NY to third-party manufacturers across five countries, a restructuring the 10-K targets for completion in the third quarter of fiscal 2026, while it separately discloses dependence on single and limited source suppliers for several key products and components.
See also: Healthcare · Medical Instruments & Supplies
From AngioDynamics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerinternational distributors74%10-K Item 1A: 'International distributors accounted for approximately 74% of international revenues for the fiscal year ended May 31, 2025.'
- HIGHSuppliersingle and limited source suppliers10-K Item 1A: 'We are dependent on single and limited source suppliers which subjects our business and results of operations to risks of supplier business interruptions.'
- MEDIUMCustomerGPO and IDN contracts10-K Item 1A: 'sales through a GPO or IDN can be significant to our business and our inability to retain contracts with our customers, or acquire additional contracts, could have a material adverse effect on our business, financial condition, results of operations and/or liquidity.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Unprofitable operations — net margin -10.0%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $12.79: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.75; Below-average business quality. Chart setup: RSI 58 mid-range, Bollinger mid-band. Prior stop was $11.87. Score 5.9/10, moderate confidence.
Take-profit target: $15.30 (+19.9% upside). Prior stop was $11.87. Stop-loss: $11.87.
Concentration risk — Customer: international distributors (74.0%); Concentration risk — Supplier: single and limited source suppliers; Quality below floor (3.8 < 4.0).
AngioDynamics, Inc. trades at a P/E of N/A (forward -59.0). TrendMatrix value score: 8.2/10. Verdict: Sell.
10 analysts cover ANGO with a consensus score of 4.1/5. Average price target: $18.
What does AngioDynamics, Inc. do?AngioDynamics designs, manufactures, and sells medical devices for cardiovascular disease and cancer treatment,...
AngioDynamics designs, manufactures, and sells medical devices for cardiovascular disease and cancer treatment, organized into Med Tech (Auryon atherectomy, NanoKnife ablation, AlphaVac/AngioVac thrombectomy) and Med Device (vascular access, ports, drainage) segments. The company sells through a direct U.S. sales force and relies on third-party distributors for international sales, which accounted for approximately 74% of international revenue in fiscal 2025. Manufacturing is centered in Queensbury, NY, with some production shifting to Costa Rica, Latvia, Italy, Israel, and China.